Logo

New Delhi Publishers

Navigation

Xadago (safinamide), Newron Pharmaceuticals

Drug Division

Indications: A monoamine oxidase type B (MAO-B) inhibitor indicated as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes.

Dosage: Initial dosage is 50 mg PO daily. After 2 weeks, may increase dose to 100 mg PO daily , based on individual need and tolerability.

Leave a Reply

Your email address will not be published. Required fields are marked *

19 − 14 =


DNA Digestion Experiment


Our Facebook Page

About Us

Bio Frontiers is a unique endeavor to chisel and shape contemporary outlooks in Biology. It is a Bi-monthly magazine dedicated to bringing the evolving facets of Biology to its wide gamut of readers. We focus on helping our readers to gain a better understanding of the fundamental concepts in Biology and develop on that. It is an undertaking “by the Biologists and for the growing Biologists”.

January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  

Locate Us

Contact Info

  • Bio Frontiers
    New Delhi Publishers
    Head Office: 90 Sainik Vihar, Mohan Garden,
    Uttam Nagar, New Delhi-110059
    Corporate Office: 7/28, Room No: 208,
    Vardaan House,Ansari Road,
    Daryaganj New Delhi-110002
  • Email: biofrontierse20@gmail.com
  • Website: https://bio-frontiers.com
© 2018. All Rights Reserved.